In oncology, its identification of spatially resolved therapeutic targets—such as VEGFA and CD74 in glioblastoma, or ARL2 and TMEM145 in breast cancer—highlights its potential to uncover microenvironment-specific drivers of disease progression. This evidence concerns the gene ARL2 and glioblastoma.